Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: A workshop report the RPPA (Reverse Phase Protein Array) Society

Rehan Akbani, Karl Friedrich Becker, Neil Carragher, Ted Goldstein, Leanne De Koning, Ulrike Korf, Lance Liotta, Gordon Mills, Satoshi S. Nishizuka, Michael Pawlak, Emanuel F. Petricoin, Harvey B. Pollard, Bryan Serrels, Jingchun Zhu

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Reverse phase protein array (RPPA) technology introduced a miniaturized "antigen-down" or "dot-blot" immunoassay suitable for quantifying the relative, semi-quantitative or quantitative (if a well-accepted reference standard exists) abundance of total protein levels and post-translational modifications across a variety of biological samples including cultured cells, tissues, and body fluids. The recent evolution of RPPA combined with more sophisticated sample handling, optical detection, quality control, and better quality affinity reagents provides exquisite sensitivity and high sample throughput at a reasonable cost per sample. This facilitates large-scale multiplex analysis of multiple post-translational markers across samples from in vitro, preclinical, or clinical samples. The technical power of RPPA is stimulating the application and widespread adoption of RPPA methods within academic, clinical, and industrial research laboratories. Advances in RPPA technology now offer scientists the opportunity to quantify protein analytes with high precision, sensitivity, throughput, and robustness. As a result, adopters of RPPA technology have recognized critical success factors for useful and maximum exploitation of RPPA technologies, including the following: • preservation and optimization of pre-analytical sample quality, • application of validated high-affinity and specific antibody (or other protein affinity) detection reagents, • dedicated informatics solutions to ensure accurate and robust quantification of protein analytes, and • quality-assured procedures and data analysis workflows compatible with application within regulated clinical environments. In 2011, 2012, and 2013, the first three Global RPPA workshops were held in the United States, Europe, and Japan, respectively. These workshops provided an opportunity for RPPA laboratories, vendors, and users to share and discuss results, the latest technology platforms, best practices, and future challenges and opportunities. The outcomes of the workshops included a number of key opportunities to advance the RPPA field and provide added benefit to existing and future participants in the RPPA research community. The purpose of this report is to share and disseminate, as a community, current knowledge and future directions of the RPPA technology.

Original languageEnglish (US)
Pages (from-to)1625-1643
Number of pages19
JournalMolecular and Cellular Proteomics
Volume13
Issue number7
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Protein Array Analysis
Translational Medical Research
Education
Proteins
Technology
Informatics
Antibody Affinity
Workflow
Industrial laboratories
Throughput
Body Fluids
Post Translational Protein Processing
Practice Guidelines
Immunoassay
Research
Industrial research
Quality Control
Cultured Cells
Body fluids
Japan

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Molecular Biology

Cite this

Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research : A workshop report the RPPA (Reverse Phase Protein Array) Society. / Akbani, Rehan; Becker, Karl Friedrich; Carragher, Neil; Goldstein, Ted; De Koning, Leanne; Korf, Ulrike; Liotta, Lance; Mills, Gordon; Nishizuka, Satoshi S.; Pawlak, Michael; Petricoin, Emanuel F.; Pollard, Harvey B.; Serrels, Bryan; Zhu, Jingchun.

In: Molecular and Cellular Proteomics, Vol. 13, No. 7, 01.01.2014, p. 1625-1643.

Research output: Contribution to journalArticle

Akbani, R, Becker, KF, Carragher, N, Goldstein, T, De Koning, L, Korf, U, Liotta, L, Mills, G, Nishizuka, SS, Pawlak, M, Petricoin, EF, Pollard, HB, Serrels, B & Zhu, J 2014, 'Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: A workshop report the RPPA (Reverse Phase Protein Array) Society', Molecular and Cellular Proteomics, vol. 13, no. 7, pp. 1625-1643. https://doi.org/10.1074/mcp.O113.034918
Akbani, Rehan ; Becker, Karl Friedrich ; Carragher, Neil ; Goldstein, Ted ; De Koning, Leanne ; Korf, Ulrike ; Liotta, Lance ; Mills, Gordon ; Nishizuka, Satoshi S. ; Pawlak, Michael ; Petricoin, Emanuel F. ; Pollard, Harvey B. ; Serrels, Bryan ; Zhu, Jingchun. / Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research : A workshop report the RPPA (Reverse Phase Protein Array) Society. In: Molecular and Cellular Proteomics. 2014 ; Vol. 13, No. 7. pp. 1625-1643.
@article{46b88fc9e79b43e1b61b8d9d73b751b0,
title = "Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: A workshop report the RPPA (Reverse Phase Protein Array) Society",
abstract = "Reverse phase protein array (RPPA) technology introduced a miniaturized {"}antigen-down{"} or {"}dot-blot{"} immunoassay suitable for quantifying the relative, semi-quantitative or quantitative (if a well-accepted reference standard exists) abundance of total protein levels and post-translational modifications across a variety of biological samples including cultured cells, tissues, and body fluids. The recent evolution of RPPA combined with more sophisticated sample handling, optical detection, quality control, and better quality affinity reagents provides exquisite sensitivity and high sample throughput at a reasonable cost per sample. This facilitates large-scale multiplex analysis of multiple post-translational markers across samples from in vitro, preclinical, or clinical samples. The technical power of RPPA is stimulating the application and widespread adoption of RPPA methods within academic, clinical, and industrial research laboratories. Advances in RPPA technology now offer scientists the opportunity to quantify protein analytes with high precision, sensitivity, throughput, and robustness. As a result, adopters of RPPA technology have recognized critical success factors for useful and maximum exploitation of RPPA technologies, including the following: • preservation and optimization of pre-analytical sample quality, • application of validated high-affinity and specific antibody (or other protein affinity) detection reagents, • dedicated informatics solutions to ensure accurate and robust quantification of protein analytes, and • quality-assured procedures and data analysis workflows compatible with application within regulated clinical environments. In 2011, 2012, and 2013, the first three Global RPPA workshops were held in the United States, Europe, and Japan, respectively. These workshops provided an opportunity for RPPA laboratories, vendors, and users to share and discuss results, the latest technology platforms, best practices, and future challenges and opportunities. The outcomes of the workshops included a number of key opportunities to advance the RPPA field and provide added benefit to existing and future participants in the RPPA research community. The purpose of this report is to share and disseminate, as a community, current knowledge and future directions of the RPPA technology.",
author = "Rehan Akbani and Becker, {Karl Friedrich} and Neil Carragher and Ted Goldstein and {De Koning}, Leanne and Ulrike Korf and Lance Liotta and Gordon Mills and Nishizuka, {Satoshi S.} and Michael Pawlak and Petricoin, {Emanuel F.} and Pollard, {Harvey B.} and Bryan Serrels and Jingchun Zhu",
year = "2014",
month = "1",
day = "1",
doi = "10.1074/mcp.O113.034918",
language = "English (US)",
volume = "13",
pages = "1625--1643",
journal = "Molecular and Cellular Proteomics",
issn = "1535-9476",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "7",

}

TY - JOUR

T1 - Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research

T2 - A workshop report the RPPA (Reverse Phase Protein Array) Society

AU - Akbani, Rehan

AU - Becker, Karl Friedrich

AU - Carragher, Neil

AU - Goldstein, Ted

AU - De Koning, Leanne

AU - Korf, Ulrike

AU - Liotta, Lance

AU - Mills, Gordon

AU - Nishizuka, Satoshi S.

AU - Pawlak, Michael

AU - Petricoin, Emanuel F.

AU - Pollard, Harvey B.

AU - Serrels, Bryan

AU - Zhu, Jingchun

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Reverse phase protein array (RPPA) technology introduced a miniaturized "antigen-down" or "dot-blot" immunoassay suitable for quantifying the relative, semi-quantitative or quantitative (if a well-accepted reference standard exists) abundance of total protein levels and post-translational modifications across a variety of biological samples including cultured cells, tissues, and body fluids. The recent evolution of RPPA combined with more sophisticated sample handling, optical detection, quality control, and better quality affinity reagents provides exquisite sensitivity and high sample throughput at a reasonable cost per sample. This facilitates large-scale multiplex analysis of multiple post-translational markers across samples from in vitro, preclinical, or clinical samples. The technical power of RPPA is stimulating the application and widespread adoption of RPPA methods within academic, clinical, and industrial research laboratories. Advances in RPPA technology now offer scientists the opportunity to quantify protein analytes with high precision, sensitivity, throughput, and robustness. As a result, adopters of RPPA technology have recognized critical success factors for useful and maximum exploitation of RPPA technologies, including the following: • preservation and optimization of pre-analytical sample quality, • application of validated high-affinity and specific antibody (or other protein affinity) detection reagents, • dedicated informatics solutions to ensure accurate and robust quantification of protein analytes, and • quality-assured procedures and data analysis workflows compatible with application within regulated clinical environments. In 2011, 2012, and 2013, the first three Global RPPA workshops were held in the United States, Europe, and Japan, respectively. These workshops provided an opportunity for RPPA laboratories, vendors, and users to share and discuss results, the latest technology platforms, best practices, and future challenges and opportunities. The outcomes of the workshops included a number of key opportunities to advance the RPPA field and provide added benefit to existing and future participants in the RPPA research community. The purpose of this report is to share and disseminate, as a community, current knowledge and future directions of the RPPA technology.

AB - Reverse phase protein array (RPPA) technology introduced a miniaturized "antigen-down" or "dot-blot" immunoassay suitable for quantifying the relative, semi-quantitative or quantitative (if a well-accepted reference standard exists) abundance of total protein levels and post-translational modifications across a variety of biological samples including cultured cells, tissues, and body fluids. The recent evolution of RPPA combined with more sophisticated sample handling, optical detection, quality control, and better quality affinity reagents provides exquisite sensitivity and high sample throughput at a reasonable cost per sample. This facilitates large-scale multiplex analysis of multiple post-translational markers across samples from in vitro, preclinical, or clinical samples. The technical power of RPPA is stimulating the application and widespread adoption of RPPA methods within academic, clinical, and industrial research laboratories. Advances in RPPA technology now offer scientists the opportunity to quantify protein analytes with high precision, sensitivity, throughput, and robustness. As a result, adopters of RPPA technology have recognized critical success factors for useful and maximum exploitation of RPPA technologies, including the following: • preservation and optimization of pre-analytical sample quality, • application of validated high-affinity and specific antibody (or other protein affinity) detection reagents, • dedicated informatics solutions to ensure accurate and robust quantification of protein analytes, and • quality-assured procedures and data analysis workflows compatible with application within regulated clinical environments. In 2011, 2012, and 2013, the first three Global RPPA workshops were held in the United States, Europe, and Japan, respectively. These workshops provided an opportunity for RPPA laboratories, vendors, and users to share and discuss results, the latest technology platforms, best practices, and future challenges and opportunities. The outcomes of the workshops included a number of key opportunities to advance the RPPA field and provide added benefit to existing and future participants in the RPPA research community. The purpose of this report is to share and disseminate, as a community, current knowledge and future directions of the RPPA technology.

UR - http://www.scopus.com/inward/record.url?scp=84904094390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904094390&partnerID=8YFLogxK

U2 - 10.1074/mcp.O113.034918

DO - 10.1074/mcp.O113.034918

M3 - Article

C2 - 24777629

AN - SCOPUS:84904094390

VL - 13

SP - 1625

EP - 1643

JO - Molecular and Cellular Proteomics

JF - Molecular and Cellular Proteomics

SN - 1535-9476

IS - 7

ER -